---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-006972"
form_type: "8-K"
ticker: "NAGE"
cik: "0001386570"
company_name: "Niagen Bioscience, Inc."
filed_at: "2023-03-08T23:59:59+00:00"
generated_at: "2026-06-18T08:17:44.599416+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ChromaDex Q4 revenue $21.0M (+18% YoY), Adj EBITDA turns positive at $0.4M

## Summary
- Q4 net sales $21.0M (+18% YoY); Tru Niagen sales $16.1M (+14% YoY).
- Net loss narrowed to $1.4M ($0.02 loss per share) from $5.3M loss a year ago.
- Adjusted EBITDA profit $0.4M, a $3.8M improvement vs Q4 2021 loss.
- Full year net sales $72.0M (+7%); net loss $16.5M, improved $6.6M YoY.
- Signed long-term supply deal with Nestlé Health Science; entered China via Sinopharm Xingsha.

## SEC filing metadata
- accession: 0001628280-23-006972
- form_type: 8-K
- ticker: NAGE
- cik: 0001386570
- company_name: Niagen Bioscience, Inc.
- filed_at: 2023-03-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1386570/000162828023006972/0001628280-23-006972-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1386570/000162828023006972/cdxc-20230308.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-006972
- JSON: https://secwatch.observer/filing/0001628280-23-006972.json
- Plain text: https://secwatch.observer/filing/0001628280-23-006972.txt

## Key facts
- Earnings Releases
  Niagen Bioscience, Inc. reported financial results for fourth quarter and the year ended December 31, 2022.
  - Period: fourth quarter and the year ended December 31, 2022
  - Result: reported results
  source text: On March 8, 2023, ChromaDex Corporation (the “Company”) issued a press release announcing its financial results for the fourth quarter and the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1386570/000162828023006972/0001628280-23-006972-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.